You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BIOSYNESIS, INC. Topic: NIAID
Project Summary/Abstract Members of the Candida genus of fungi form part of the normal human microbiota but are also opportunistic pathogens capable of causing serious mucosal and systemic infections. Candida cells grow and divide in suspension (planktonic) cultures, but they also form resilient and drug resistant biofilms – organized, tightly- packed communities of cells that attach to surfaces ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBCSBC: DNATWO, Inc. Topic: NCI
DNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York CitySBC: HBI SOLUTIONS INC. Topic: 100
ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Medical Predictive Science Corporation Topic: NICHD
Project Summary/Abstract: Clinical Decision Support System to Optimize Neonatal Nutrition and Growth Nutrition, defined as energy, macronutrients (protein, fat, and carbohydrates), and micronutrients (e.g., electrolytes), is a critical feature of care for preterm infants in the neonatal intensive unit (NICU). Inadequate nutrition is associated with growth and neurodevelopmental impairment, and inc ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: NCATS
ABSTRACT Remote trials are led and coordinated by a local investigative team, but are based remotely, typically in the participant’s home. Remote trials offer several advantages over traditional in-person trials including: 1) a wider participant pool, 2) reduced regulatory hurdles, and 3) reduced participant burden. Remote trials face one key methodological limitation: the need for biomarker col ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: NEUIMMUNE BIOLOGICS, INC. Topic: NHLBI
ABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1 antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which presents supply chain and contaminant risks. This could be remedied wi ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Olfa Thera, Inc. Topic: NIDA
Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorderSBC: ELEVEN THERAPEUTICS CORP Topic: NIDA
Abstract There is a significant need for new treatments for opioid use disorder (OUD) to manage patients abusing heroin, fentanyl, oxycodone and related drugs. Buprenorphine and methadone are both effective medications for OUD but are agonists with potential for abuse and diversion, and with methadone the risk of respiratory depression and overdose death. Moreover, these compounds are not effectiv ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Brixton Biosciences, Inc. Topic: NIAMS
Project SummaryTotal knee arthroplasty (TKA) is one of the most commonly performed orthopedic surgeries to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. In the United States, over 700,000 TKA procedures are performed each year. Most patients experience significant pain after TKA. To manage this pain, patients are commonly prescribed opioids, contributing to a ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: NIDDK
PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity, and engender fewer side effects than traditional small molecules. This has fueled interest in peptides filling the gap between ‘biologics’ and small molecules, as peptide-based compounds have key desired properties that are distinct both of the other classes. A major challenge remains to extend the short half-life of na ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health